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The association of DNA methylation with
body mass index: distinguishing between
predictors and biomarkers
Zoe E. Reed1*, Matthew J. Suderman1, Caroline L. Relton1, Oliver S. P. Davis1,2 and Gibran Hemani1
Abstract
Background: DNA methylation is associated with body mass index (BMI), but it is not clear if methylation scores
are biomarkers for extant BMI or predictive of future BMI. Here, we explore the causal nature and predictive utility
of DNA methylation measured in peripheral blood with BMI and cardiometabolic traits.
Methods: Analyses were conducted across the life course using the ARIES cohort of mothers (n = 792) and
children (n = 906), for whom DNA methylation and genetic profiles and BMI at multiple time points (3 in children
at birth, in childhood and in adolescence; 2 in mothers during pregnancy and in middle age) were available.
Genetic and DNA methylation scores for BMI were derived using published associations between BMI and DNA
methylation and genotype. Causal relationships between methylation and BMI were assessed using Mendelian
randomisation and cross-lagged models.
Results: The DNA methylation scores in adult women explained 10% of extant BMI variance. However, less extant
variance was explained by scores generated in the same women during pregnancy (2% BMI variance) and in older
children (15–17 years; 3% BMI variance). Similarly, little extant variance was explained in younger children (at birth
and at 7 years; 1% and 2%, respectively). These associations remained following adjustment for smoking exposure
and education levels. The DNA methylation score was found to be a poor predictor of future BMI using linear and
cross-lagged models, suggesting that DNA methylation variation does not cause later variation in BMI. However,
there was some evidence to suggest that BMI is predictive of later DNA methylation. Mendelian randomisation
analyses also support this direction of effect, although evidence is weak. Finally, we find that DNA methylation
scores for BMI are associated with extant cardiometabolic traits independently of BMI and genetic score.
Conclusion: The age-specific nature of DNA methylation associations with BMI, lack of causal relationship and
limited predictive ability of future BMI indicate that DNA methylation is likely influenced by BMI and might more
accurately be considered a biomarker of BMI and related outcomes rather than a predictor. Future epigenome-wide
association studies may benefit from further examining associations between early DNA methylation and later
health outcomes.
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Background
Obesity has a considerable burden on healthcare and
has been shown to be predictive of mortality [1]. In re-
cent years, there has been a gradual increase in body
mass index (BMI) in many countries [2], and interven-
tions to decrease BMI have had limited success [3, 4].
Predicting BMI early on and performing targeted in-
terventions are an alternative strategy that could be
more effective.
The aetiology of BMI comprises both genetic and
environmental factors, with heritability likely below 0.5
[5, 6]. It has been suggested that natural variation in
DNA methylation levels may be a risk factor for certain
diseases and plays a role in the phenotypic variation of
many traits [7–9]. In some cases, DNA methylation may
provide the molecular link between environmental fac-
tors and associated disease risk, for example, recent
studies have suggested that DNA methylation may be
the mechanism allowing environmental factors or
increased BMI to lead to obesity-related health out-
comes [10–12]. Therefore, it could be useful as a pre-
dictor of such health outcomes.
Recent studies [13–15] suggest that DNA methylation
associates with BMI trait variance independent of gen-
etic variation. Associated genes have been shown to be
involved in processes such as metabolism, inflammation,
metabolic disease and cardiovascular disease amongst
others. This suggests that associated DNA methylation
loci may belong to causal pathways linking BMI and
metabolic, cardiovascular and other obesity-related
health outcomes, but this requires further exploration.
Since genetic variants are fixed at conception, genetic
variants associated with BMI can be used early in life to
predict later BMI [16]. The relationship of DNA methy-
lation at BMI associated loci, however, is more complex.
Methylation levels vary over time and may change in
response to environmental or phenotypic changes so
earlier methylation variation is not guaranteed to predict
later BMI levels. Recent work [14] has suggested that
change in BMI is more likely to be causal for changes in
DNA methylation than vice versa. This would suggest
that current DNA methylation scores are simply bio-
markers for extant BMI. However, the utility of DNA
methylation as a predictor for future trajectories of BMI
would be of considerably greater utility.
The first aim of our study was to investigate if there is
a temporal association between DNA methylation and
BMI. We approached this question by using genome-
wide DNA methylation profiles from the Accessible
Resource for Integrated Epigenomic Studies (ARIES)
[17] subset of the Avon Longitudinal Study of Parents
and Children (ALSPAC) [18, 19]. ALSPAC is a prospect-
ive cohort of children born in the former county of
Avon, England, during 1991 and1992. DNA methylation
profiles were generated in children from blood collected
at three time points (birth, childhood, adolescence) and
from their mothers at two time points (during pregnancy
and at middle age). We used these DNA methylation
profiles along with multiple measurements of BMI gen-
etic profiles to determine if DNA methylation predicted
BMI later in life, independently of genetic variation and
BMI itself, and vice versa. In doing so, our objective was
to determine if DNA methylation is a predictor for BMI
or simply a biomarker that proxies current or previous
BMI values.
DNA methylation scores for BMI may be useful for
the detection of adverse health outcomes related to BMI.
For example, Wahl et al. found that DNA methylation
could be used to identify individuals at high risk of inci-
dent type 2 diabetes, independently of other explanatory
factors, including BMI itself [14]. Therefore, the second
aim of our study was to see if DNA methylation scores
for BMI contributed anything above BMI itself in pre-
dicting related adverse health outcomes.
Methods
Cohort description
We used children’s and mothers’ data from the Avon
Longitudinal Study of Parents and Children (ALSPAC)
cohort in this study [18, 19]. The ALSPAC cohort is a
prospective birth cohort study in which 14,541 pregnant
women living in Avon, UK, with an expected delivery
date from 1 April 1991 to 31 December 1992, were ini-
tially recruited. Of these, 13,988 children were still alive
1 year later and have been followed up with regular
questionnaires and clinical measures, providing behav-
ioural, lifestyle and biological data. When the children
were approximately 7 years of age, an attempt was made
to bolster the initial sample with eligible cases who had
failed to join the study originally. As a result, when con-
sidering variables collected after age 7, the total sample
size for those alive at 1 year of age is 14,901. The study
website contains details of all the data that is available
through a fully searchable data dictionary and variable
search tool (http://www.bristol.ac.uk/alspac/researchers/
our-data/).
We only included participants that were also in the
sub-study Accessible Resource for Integrated Epige-
nomic Studies (ARIES), where methylation data was
available for these individuals [17]. After excluding those
without methylation or phenotypic data and those that
had withdrawn consent, we had data available for ana-
lyses from 823 children at birth, 906 for childhood (age
7), 770 for adolescence (age 15) and 792 for pregnant
mothers and 726 for middle-aged mothers. The mean
age and BMI are presented in Table 1. Sex is also
included for children only, as adults were all female.
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Ethics
Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local
Research Ethics Committees. Informed consent for the
use of data collected via questionnaires and clinics was
obtained from participants following the recommenda-
tions of the ALSPAC Ethics and Law Committee at the
time.
Phenotypic measures
The time points investigated in this study are pregnancy
and middle-age data for the mothers and birth and
childhood (age 7) and adolescence (ages 15–17 for
methylation data and age 17 for BMI data) data for the
children.
Measures of height and weight were collected at
research clinic visits. Height was measured to the nearest
millimetre using the Harpenden Stadiometer. Weight
was measured using the Tanita Body Fat Analyser to the
nearest 50 g. BMI was calculated by dividing weight
(kilogrammes) by height (metres) squared (kg/m2). For
measurements at birth, birth weight was collected and is
used here instead of BMI.
Data for smoking and highest education level of
mothers, age, sex, sample type and cell type proportions
(B cell, CD4T, CD8T, Gran, Mono and NK) were used
as covariates in analyses (for children, information on
matched mothers smoking and maternal education were
used). Various answers from questions regarding smok-
ing in mothers (in pregnancy and currently) were used,
from the questionnaire data. These included the number
of cigarettes smoked per day before pregnancy, during
the first 3 months of pregnancy and the number of ciga-
rettes smoked in the last 2 weeks during or just after
pregnancy. These measures were combined to create a
variable for whether the mother smoked in pregnancy.
We also used data on the number of cigarettes smoked
per day, whether they responded as being a current
smoker and the time passed since they stopped smoking
if this was within the last 12 months to create a variable
for current or recent (within the last 12 months) smoker.
Education level for the mothers was also taken from
questionnaire data, where participants were asked “What
educational qualifications do you, your partner, your
mother, and your father have?” They were asked to
select all options that applied to them, and we used the
highest education qualification for the participant. The
options for this were CSE/none, vocational, O level, A
level or degree.
Variables for cardiovascular outcomes for middle-aged
mothers and adolescents were also used. These variables
were from blood samples, obtained during clinic visits
and included fasting glucose and insulin, triglycerides
and low-density lipoprotein (LDL). Sitting diastolic and
systolic blood pressures (SBP) from the right arm were
collected during clinic visits. An Omron M6 upper arm
blood pressure/pulse monitor was used to take 2 read-
ings of blood pressure and then mean values were used.
The data for triglycerides, glucose and insulin were
skewed so we log transformed these data for use in
analyses.
Methylation data
Methylation profiling in the ARIES subset was con-
ducted using DNA samples from blood taken at clinic
visits or after delivery from the umbilical cord in the
case of the birth time point. Blood from 1018 mother–
child pairs (children at three time points and their
mothers at two time points) were selected for analysis as
part of the Accessible Resource for Integrative Epige-
nomic Studies (ARIES, http://www.ariesepigenomics.org.
uk/) [17]. Following DNA extraction, samples were
bisulphite converted using the Zymo EZ DNA Methyla-
tion™ kit (Zymo, Irvine, CA, USA). Following conversion,
genome-wide methylation was measured using the Illu-
mina Infinium HumanMethylation450 (HM450) Bead-
Chip. The arrays were scanned using an Illumina iScan,
with initial quality review using GenomeStudio. ARIES
data were pre-processed and normalised using the meffil
R package [20]. ARIES consists of 5469 DNA methyla-
tion profiles obtained from 1022 mother–child pairs
measured at five time points. Low-quality profiles were
removed from further processing, and the remaining
4593 profiles were normalised using the Functional
Normalization algorithm [21] with the top 10 control
probe principal components. From the ARIES dataset,
sample type and normalised methylation data was
extracted, and cell type proportion data were estimated
Table 1 Cohort description
Children Mothers
Birth
(n = 823)
Childhood
(n = 906)
Adolescence
(n = 770)
Pregnancy
(n = 792)
Middle-age
(n = 726)
Mean age in years (SD) NA 7.45 (0.15) 17.35 (0.88) 28.87 (4.30) 47.66 (4.26)
Percentage of females 51.03% 50.44% 53.38% 100% 100%
Mean BMI (kg/m2) or birthweight (grams) (SD) 3490.93 (477.76) 16.20 (2.04) 22.58 (3.83) 22.72 (3.63) 26.41 (5.09)
SD standard deviation, BMI body mass index
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using the Houseman method [22]. Full details of the
pre-processing and normalisation of ARIES has been
described previously [20].
Genotyping
Genetic data were collected from the blood samples
obtained in clinic visits. Genotyping was conducted with
the Illumina HumanHap550 quad chip for children and
the Illumina human660W-quad array for mothers. Qual-
ity control measures were carried out and haplotypes
estimated using ShapeIT. A phased version of the 1000
genomes reference panel from the Impute2 reference
data repository was used, and imputation of the target
data was performed with this, using all reference haplo-
types. Following imputation, variants were only retained
if they had info scores > 0.8 and minor allele frequency
> 0.01 and were then converted to best-guess genotype
calls. A large proportion of the cohort has genome-wide
data from these samples, and a subset of this data was
used in this study [18].
Genetic and epigenetic scores
To investigate whether reported DNA methylation asso-
ciations with BMI could be observed in an independent
cohort, we calculated DNA methylation scores from
published effect sizes for 135 CpG sites from the Men-
delson et al. [15] meta-analysis of DNA methylation and
BMI. Weighted scores were obtained for each ARIES
methylation profile by multiplying the CpG site methyla-
tion levels in that profile with the corresponding pub-
lished effects estimates and then summing the products.
Genetic scores were similarly derived using effect sizes
for 97 SNPs from the GIANT consortium BMI genome-
wide association study (GWAS) [23]. Scores were cre-
ated using Plink V1.9 (https://www.cog-genomics.org/
plink2) with the score and sum commands, which
weights alleles by the corresponding effect size and then
sums these to get scores per individual. However, one of
the SNPs (rs12016871) did not meet imputation score
filters (imputation quality score greater than 0.8 and
minor allele frequency greater than 0.01), so the score
was constructed using only 96 SNPs.
To perform simplified versions of Mendelian random-
isation (MR), we used summary statistics from methyla-
tion quantitative trait loci (mQTL). mQTLs are genetic
variants associated with DNA methylation [24]. To iden-
tify mQTLs, we looked these up in mQTLdb [25], which
contains mQTLs below a conservative p value threshold
of 1E−07. If multiple mQTLs were identified for an indi-
vidual CpG site, the one with the lowest p value reported
in the GIANT study for BMI was used as the mQTL for
the MR analysis. If these mQTLs were unavailable, then
proxies of these SNPs were obtained. These were SNPs
with the next lowest p value for that CpG, which were
also present in the BMI GWAS data. We used the last p
value available in the BMI GWAS for each mQTL to
maximise power. Of the 135 CpG sites we queried, 89
had an instrument at this threshold.
Statistical analysis
Observational associations at the same time point
Linear regression models, with adjustments for covari-
ates, were used to test observational associations. When
testing for association between genetic and/or methyla-
tion scores of BMI, BMI was the dependent variable and
the methylation and/or genetic score was the independ-
ent variable. For models including a genetic score, age
was included as a covariate. For models including a
methylation score, the covariates included were age,
sample type and estimated blood cell type proportions.
Sex was additionally included as a covariate in all models
analysing child data. For predicting BMI, BMI was used
as the dependent variable, and when predicting methyla-
tion, methylation score was used as the dependent vari-
able. We additionally tested the association of each of
the CpGs with BMI for mothers at middle-age and chil-
dren in adolescence.
To compare the relative contributions of genetic score
and methylation score to BMI, an analysis of variance
(ANOVA) test was carried out comparing the following
three models, with the full model (model 3) being com-
pared to each of the reduced models (models 1 and 2):
1. BMI ~ methylation score + covariates
2. BMI ~ genetic score + covariates
3. BMI ~ methylation score + genetic score +
covariates
Finally, we investigated how BMI and DNA methyla-
tion change over the life course. Firstly, we calculated
correlations of BMI and DNA methylation score at dif-
ferent time points for mothers and children separately.
We then examined the correlation of BMI and DNA
methylation scores between paired children and mothers
at the different time points. Thirdly, we also calculated
correlations for all individual CpG sites across the differ-
ent time points and between paired child’s cord blood
DNA and mother’s antenatal peripheral blood DNA
values.
Observational associations across the life course
To investigate whether DNA methylation might be
predictive of later BMI or vice versa, we assessed
associations between different time points in mothers
and children, using linear regression models, similar
to those used in the observational analyses within
the same time point.
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Exploration of a causal relationship between BMI and DNA
methylation
Cross-lagged model We analysed the temporal rela-
tionship of BMI and DNA methylation, using a cross-
lagged model. This approach allows exploration of the
relationships between earlier BMI and later methylation
score in two separate systems, one in the children (using
childhood and adolescence) and one in the mothers
(using the antenatal and middle age time points). The R
package OpenMx (version 2.13.2) [26] was used to build
a cross-lagged model, shown in Figs. 3 and 4. Values for
each of the free parameters or paths are estimated in the
model. The paths were from earlier BMI to methylation
at the same time point, later methylation and later BMI;
from earlier methylation to later BMI and methylation;
and from later BMI to methylation at the same time
point. Each path was sequentially tested in a sub model
analysis, where that path was fixed to 0, and this sub
model was compared against the full model using a like-
lihood ratio test. If a sub model had a significantly worse
fit, then that path was retained, but otherwise dropped
because it was not important to the overall system.
Mendelian randomisation To investigate causal infer-
ence more directly, an approach based on MR was
adopted. To test if changes in BMI cause changes in
DNA methylation, we calculated genetic scores for BMI,
as previously described, and tested the association of this
score with each of the 135 BMI-associated CpG sites.
We used a Bonferroni-adjusted p value threshold of 3.7E
−04 to account for multiple testing. A Fisher’s test was
then applied to combine the association p values for all
135 association tests. To increase power, the adolescent
and middle-aged mother’s data was subsequently com-
bined, and the association was tested again using a
mixed model to account for relatedness.
Two-sample MR was applied to explore the reverse
direction, i.e. a causal effect of DNA methylation on
BMI. In this approach, summary statistics from the BMI
GWAS were obtained for the mQTLs (or proxies of
these, if these SNPs were unavailable) for the 135 BMI-
associated CpG sites. We also used a Bonferroni-
adjusted p value threshold of 3.7E−04 to account for
multiple testing in these analyses.
Confounder analysis
To investigate whether any associations found between
methylation and BMI were due to confounding by smok-
ing or education, we compared linear models of BMI
and DNA methylation with and without smoking (pre-
natal smoking during pregnancy for children and own
smoking for adults) and education as covariates.
Cardiovascular trait analyses
Linear regression models were used to test observa-
tional associations between the methylation and gen-
etic scores for BMI against cardiovascular outcomes.
These were performed with and without adjustment
for BMI and using other covariates, as with other
models. ANOVA tests were used to compare the rela-
tive contributions of BMI and the genetic and methy-
lation scores, and results are reported for these
comparisons.
Results
Establishing associations between DNA methylation and
BMI within time points
The methylation score for BMI, derived from the
Mendelson et al. epigenome-wide association study
(EWAS) [15], was strongly associated with BMI in
middle-aged mothers, explaining 10% of the variation
in BMI (p = 1.58E−23). The association was weaker in
mothers during pregnancy (2% variance explained, p =
2.31E−06) and in children at birth (2% variance
explained, p = 6.83E−05), childhood (1% variance
explained, p = 2.23E−04) and adolescence (3% vari-
ance explained, p = 3.91E−11). Full results are pre-
sented in Table 2. We tested the association between
each of the CpG sites and BMI for middle-aged
mothers and adolescent children and present these
results in QQ plots in Supplementary Figures 1 and 2,
respectively. We observe high inflation in these QQ
plots (λ = 7.33 in mothers and λ = 2.85 in children),
consistent with many of the DNAm sites having an
association. In addition, we plotted the effect size from
the Mendelson et al. paper [15] against those in ARIES
for middle-aged mothers and adolescent children
(Supplementary Figures 3 and 4, respectively) and
found that they were generally in the same direction
and of similar magnitude.
Genetic scores for BMI, derived from published
GWAS summary statistics [23], were also associated
with BMI, with the strongest association found for chil-
dren in adolescence with 5% variance explained in BMI
(p = 2.12E−10) and weaker associations found at all
other time points (see Table 2 for full results).
The genetic and methylation score associations
appear to be mostly independent (Table 3), as the
combined model with both genetic and methylation
scores performed better than both the methylation
score (ANOVA test p values ranged from 1.93E−10 to
0.04) and genetic score models (ANOVA test p values
ranged from 4.55E−21 to 1.28E−03) alone for all time
points. This validates previous findings that the geno-
type and DNA methylation explain independent sub-
sets of BMI variation [13, 15].
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Stability of phenotypic values over time and between
generations
We evaluated the extent to which individual BMI levels
correlated over time and between mothers and children.
The strongest BMI correlations were observed in
children between age 7 and adolescence and in
mothers between pregnancy and middle age (R ~
0.7). Intermediate correlations were observed be-
tween children and mothers at all time points (R ~
0.3) except birth. Lowest BMI correlations (R ~ 0.15)
were observed with birth, likely because birthweight
is a different measure than BMI (Fig. 1).
The BMI methylation score correlations exhibited
similar patterns but were generally lower than for BMI.
Strongest correlations were observed in children
between age 7 and adolescence and in mothers between
pregnancy and middle age (R ~ 0.5). All other correla-
tions were between 0.2 and 0.25. Thus, methylation
scores at birth were more highly correlated with later
time points and with maternal methylation scores than
birthweight and BMI (Fig. 2). Given the weak association
of methylation in childhood with BMI, factors other than
BMI likely contribute to the correlation of DNA methy-
lation over time and between mothers and children.
Finally, to examine whether there are particular CpG
sites that correlate more strongly over time and between
paired children and mothers, we tested the correlation of
each site at different time points (Supplementary Table 1,
Additional file 1). We observe that the median correla-
tions across all CpG sites follow a similar pattern to corre-
lations of the methylation scores over time, where the
strongest correlations were observed in children between
age 7 and adolescence and in mothers between pregnancy
and middle age (R ~ 0.2). Only these two sets of time
points have CpG sites with correlation R > 0.5. There are
six such CpG sites for each and two of these are common
to both (cg16611584, cg24145109). Both of these CpG
sites are highly correlated across all time points.
Predicting future BMI with past DNA methylation scores
We next investigated whether the BMI methylation
score was predictive of BMI at later time points or vice
versa (if BMI was predictive of methylation score at later
time points; Table 4). We observed some evidence that
methylation score in childhood could be predictive of
BMI in adolescence (p = 0.004), although the association
disappeared when adjusting for childhood BMI (p =
0.20), and there was stronger evidence for the converse,
Table 2 Associations between methylation and genetic scores and BMI/birth weight at the same time point
N Associations between methylation score and BMI/birth weight Associations between genetic score and BMI/birth
weight
Effect size1, in kg/m2 per SD in methylation
score (CI)
p value Adjusted R-
squared3
Effect size2 (CI) p value Adjusted R-
squared3
Birth4 823 69.27 (35.35, 103.18) 6.83E
−05
0.02 − 219.75 (− 412.59, −
26.90)
0.03 0.004
Childhood 906 0.25 (0.12, 0.39) 2.23E
−04
0.01 2.24 (1.45, 3.02) 2.72E
−08
0.03
Adolescence 770 0.97 (0.69, 1.26) 3.91E
−11
0.03 5.25 (3.65, 6.85) 2.12E
−10
0.05
Pregnancy 792 0.62 (0.36, 0.87) 2.31E
−06
0.02 2.91 (1.38, 4.43) 1.95E
−04
0.02
Middle-age 726 2.06 (1.67, 2.46) 1.58E
−23
0.10 4.72 (2.54, 6.90) 2.45E
−05
0.02
1From model adjusting for age (except at birth), sex (where applicable), sample type (where applicable) and cell type proportions (B cell, CD4T, CD8T, Gran, Mono and NK).
2From model adjusting for age and sex (where applicable)
3Adjusted R-squared obtained from model with only the methylation score or genetic score and no other covariates
4The effect size units for birth are grams per standard deviation in DNA methylation score
Table 3 Results from combined model and ANOVA comparing this with models for methylation and genetic scores
Combined model adjusted R-squared1 ANOVA (model 1 vs model 3) ANOVA (model 2 vs model 3)
Birth 0.03 0.04 1.56E−09
Childhood 0.04 9.03E−09 1.28E−03
Adolescence 0.08 1.93E−10 5.28E−11
Pregnancy 0.04 2.22E−04 5.36E−05
Middle age 0.12 2.77E−05 4.55E−21
1Adjusted R-squared obtained from model with both the methylation and the genetic scores and no other covariates
Model 1 includes the methylation score, model 2 includes the genetic score and model 3 is the combined model including the methylation and genetic score. All
models also included the relevant covariates
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that is, BMI in childhood predicting adolescent DNA
methylation (p = 1.52E−06 even when adjusting for
childhood methylation score). We observed the same in
the mothers between pregnancy and middle age, that is,
the association between antenatal (earlier) methylation
score and middle age (later) BMI (p = 0.02) essentially
disappears when adjusting for antenatal (earlier) BMI (p
= 0.13). Also, the association between antenatal (earlier)
BMI and middle age (later) DNA methylation is much
stronger even when adjusting for antenatal (earlier)
methylation score (p = 5.48E−11).
Exploration of temporal relationships between BMI and
DNA methylation
To further evaluate the temporal associations between
DNA methylation and BMI, we used cross-lagged models
to test which paths from earlier trait measures and scores
were important for later trait measures and scores. Agree-
ing with the results from adjusted linear models, these did
reveal a pathway between BMI in childhood and
methylation score in adolescence. Figure 3 shows the esti-
mates and variances/covariances obtained from the main
model. The only path that could be dropped from the
model without affecting model fit was between childhood
methylation and adolescent BMI (p = 0.35 for this
path and p < 1.79E−4 for all other paths; Supplemen-
tary Figure 5, Additional file 1). Cross-lagged model
fits in mothers (Fig. 4) also revealed a pathway from
(earlier) BMI in pregnancy to (later) DNA methyla-
tion in middle age. The only path that could be
dropped from the model without affecting the model
fit was from DNA methylation in pregnancy (earlier)
and BMI in middle age (later) (p = 0.20 for this path
and p < 3.65E−09 for all other paths; Supplementary
Figure 6, Additional file 1).
Mendelian randomisation does not support a causal
relationship of DNAm on BMI
We used two-sample MR to explore causal relationships
between DNA methylation and BMI (Supplementary
Fig. 1 Correlation matrix of BMI in children (birth, childhood, adolescence) and mothers (pregnancy and middle age). This correlation matrix
shows the correlations over time for BMI at all time points in children and mothers along with p values. There is a correlation of BMI in children
and mothers over time and between paired mother and children’s BMI
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Table 1, Additional file 1). Using the BMI genetic score
as an instrumental variable for BMI, we found little evi-
dence for a causal link of BMI on each of the 135 CpG
sites used to construct the methylation score (p value
range 1.63E−03 to 9.99E−01, for all time points, with a
Bonferroni-adjusted p value threshold of 3.7E−04). A
combined p value for all 135 CpG sites obtained using
Fisher’s method similarly indicated no strong association
between the genetic score and methylation (p value
range 0.82 to 1.00, for all time points). Furthermore,
even when this analysis was repeated with a mixed
model including data from both adolescents and middle-
aged mothers to increase the power (Supplementary
Table 3, Additional file 1), there was still little evidence
of association (p value range 2.13E−02 to 9.98E−01).
The reverse causal direction, methylation variation
causing BMI variation, was investigated using mQTLs
for the 135 methylation score CpG sites as instrumental
variables. These individual tests did not indicate a causal
link (Bonferroni-adjusted p value threshold of 3.7E−04;
Supplementary Table 4, Additional file 1), although
combining the test p values using Fisher’s method did
provide weak evidence for a causal association (Fisher’s
p value = 0.03).
Confounder analyses
Sensitivity analyses showed that associations between
BMI and methylation score remained unaffected by the
inclusion of potential confounders in the majority of
models (Supplementary Table 5, Additional file 1).
Smoking and education appeared to be associated with
methylation score in some models; however, most of the
associations between BMI and methylation score
survived these adjustments (p < 0.007 = 0.05/7).
Associations with cardiovascular traits
Finally, given that BMI is a risk factor for cardiovascular
disease, we tested within-time point associations
between the DNA methylation and genetic scores for
BMI and cardiovascular traits to examine the specificity
Fig. 2 Correlation matrix of methylation score in children (birth, childhood, adolescence) and mothers (pregnancy and middle age). This
correlation matrix shows the correlations over time for overall methylation score at all time points in children and mothers along with p values.
There is a correlation of methylation score in children and mothers over time and between paired mother and children’s methylation scores
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Table 4 Associations between methylation score and BMI
Time points N Unadjusted for current BMI/birthweight Adjusted for current BMI/
birthweight
Effect
size
CI p value Adjusted R-
squared1
Effect
size
CI p value
Model: Earlier methylation score predicting later BMI2
Methylation score at birth predicting BMI in
childhood
830 − 0.03 − 0.18, 0.13 0.72 − 0.0004 − 0.07 − 0.22, 0.07 0.36
Methylation score at birth predicting BMI in
adolescence
712 0.06 − 0.25, 0.36 0.70 − 0.001 − 0.05 − 0.35, 0.25 0.73
Methylation score in childhood predicting BMI in
adolescence
762 0.41 0.13, 0.69 0.004 0.005 0.13 − 0.07, 0.34 0.20
Antenatal methylation score predicting BMI in
middle-age
765 0.80 0.44, 1.17 1.92E
−05
0.02 0.19 − 0.06, 0.44 0.13
Model: Earlier birthweight or BMI predicting later methylation score3
Birthweight predicting methylation score in
childhood
814 − 0.0001 − 0.0002,
0.00004
0.17 0.003 − 0.0002 − 0.0003, −
0.00006
0.006
Birthweight predicting methylation score in
adolescence
812 0.000003 − 0.0001,
0.0001
0.96 0.002 −
0.00008
− 0.0002,
0.00005
0.22
BMI in childhood predicting methylation score in
adolescence
891 0.09 0.06, 0.12 3.05E
−09
0.02 0.06 0.04, 0.09 1.52E
−06
Antenatal BMI predicting methylation score in
middle-age
851 0.07 0.05, 0.08 1.42E
−16
0.06 0.05 0.03, 0.05 5.48E
−11
1Adjusted R-squared obtained from model with only the methylation score and no other covariates
2From model adjusting for age (except at birth), sex (where applicable), sample type (where applicable) and cell type proportions (B cell, CD4T, CD8T, Gran, Mono
and NK). Units are standard deviation in DNA methylation score per kg/m2
3From model adjusting for age (except at birth), sex (where applicable), sample type (where applicable) and cell type proportions (B cell, CD4T, CD8T, Gran, Mono
and NK). Units are kg/m2 per standard deviation in DNA methylation score for all models not including birthweight, where the units for these models are grams
per standard deviation in DNA methylation score
Fig. 3 Pathway diagram for the cross-lagged model for childhood and adolescence. This diagram shows the observed variables in boxes. Single-
headed arrows indicate linear regressions, and double-headed, curved arrows indicate variances/covariances. Estimates for the linear relationships
are shown on the arrows, as are the values for variances and covariances
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of these scores. Firstly, we observed that methylation as-
sociations were partially independent of BMI for LDL (p
= 0.02) and glucose (p = 0.03) in adolescence and tri-
glycerides (p = 3.00E−03), LDL (p = 0.01) and SBP (p =
0.05) in mothers at middle age. Similarly, we observed
that methylation associations were partially independent
of genetic effects on SBP in adolescence (p = 0.05) and
triglycerides in mothers (p = 3.27E−03) (Supplementary
Table 6, Additional file 1). We also observed that genetic
effects were partially independent of BMI for LDL (p =
0.03), glucose (0.05) and SBP (0.03) in adolescence and
triglycerides (2.01E−04), LDL (0.02) and SBP (0.02) in
mothers. Finally, we observed that the genetic effects
were partially independent of methylation and BMI for
LDL (p = 0.02) and glucose (p = 0.03) in adolescence
and triglycerides (p = 3.80E−03), LDL (p = 0.01) and
SBP (p = 0.02) in mothers (Supplementary Table 7,
Additional file 1).
Discussion
In this study, we have demonstrated strong associations
between DNA methylation and genetic scores for BMI
[15] in both adults and children. Importantly, the use of
temporal data indicates that the DNA methylation
scores are not predictive. Whilst the association between
DNA methylation scores and BMI within time point are
strong, the associations between earlier methylation
scores later BMI are weak, and these signals do not
improve the model of simply using earlier BMI as a
predictor for later BMI. Hence, it may be more appropri-
ate to term the DNA methylation score as a biomarker
rather than a cause or predictor of BMI.
We observed within-time point associations between
DNA methylation score for BMI and health outcomes
for which BMI is a risk factor. These associations were
independent of BMI and genotype, suggesting that the
DNA methylation–BMI associations might arise due to
unmeasured confounders that also influence those out-
comes. DNA methylation could be used as a biomarker
for these outcomes, above and beyond BMI and genetic
variation.
Our study builds upon previous research in this field
showing that both genetic and environmental factors
contribute to variance in BMI [5, 23]. The contribution
of the BMI genetic risk score that we find in our study is
in line with those found in other studies [13, 27, 28].
Previous work investigating the relationship between
DNA methylation and BMI has found associations with
specific DNA methylation sites [10–12]. However,
results from these studies are fairly inconsistent, and
practical implications of these associations have not yet
been identified [29]. In extension of this previous
research, we have used 135 CpG sites, identified in an
EWAS meta-analysis [15], to create methylation scores
that are also associated with BMI in an independent
cohort. The main novel component of our study is that
we look across the life course in children and adults.
Another study investigating DNA methylation profile
Fig. 4 Pathway diagram for the cross-lagged model for pregnancy and middle-aged mothers. This diagram shows the observed variables in
boxes. Single-headed arrows indicate linear regressions, and double-headed, curved arrows indicate variances/covariances. Estimates for the linear
relationships are shown on the arrows, as are the values for variances and covariances
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and obesity in children aged 6–14 years also found an
association between childhood obesity and a separate set
of differentially methylated CpG sites, supporting our
finding that DNA methylation is associated with BMI in
adolescents [30]. Our findings in younger children were
however weaker and could be due to basing our analysis
on methylation at CpG sites associated with BMI in
adults.
We have also investigated the nature of these associa-
tions further and found that there may be some predict-
ive capability of earlier BMI to later DNA methylation at
multiple time points; however, we found no evidence to
suggest this association is causal, which could be due to
several reasons. Firstly, it may be that there is a lack of
power in these analyses for MR to detect a causal rela-
tionship. The Wahl et al. paper [14] suggests that with
larger sample sizes, the direction of effect is likely to be
from BMI to DNA methylation. Therefore, it is possible
that with a larger sample size, we could confirm this dir-
ection of causality. It could also be that there are other
unknown confounders, which are mediating this effect,
and future research should focus on investigating this
further. Our MR analyses suggest a weak aggregate
causal association from DNA methylation to BMI; how-
ever, due to the DNAm instruments being enriched for
genic regions, this association is unlikely to be stronger
than expected against a more appropriate null that
reflects that BMI is more strongly influenced by genetic
variants in genic regions [23]. We also found associa-
tions of the BMI DNAm scores with cardiovascular out-
comes. If BMI causes changes in DNAm, as our analyses
seem to suggest, then DNAm changes may fall on the
causal pathway between BMI and these cardiovascular
outcomes. Therefore, DNAm scores may have potential
use as predictors of cardiovascular outcomes, although
generalisability to other populations would need to be
confirmed. This has been suggested in previous studies
for diabetes [14, 31] and insulin resistance [32].
Limitations
This study is subject to a number of limitations. Firstly,
whilst the size of the ARIES cohort is larger than or
equivalent to samples used in other DNA methylation
studies, it may still be too small to detect some associa-
tions, and this may be why we do not find any causal
association for BMI to DNA methylation, as discussed
above. The ARIES mQTL database used in the two-
sample MR had a total sample size of 3948, although
this was split across three time points in approximately
the same children and two time points in the mothers.
We used the GIANT cohort for BMI in the two-sample
MR and included 235,522 participants in these analyses.
The GIANT sample size is much larger and therefore it
is difficult to directly compare the strength of causal
evidence in each direction between these samples. Sec-
ondly, whilst it is a strength of our study that we use
multiple time points, in the mothers, one of these is dur-
ing pregnancy, so these findings may not be generalis-
able outside of pregnancy or generalisable to males. As
with any epidemiological study, there may also be meas-
urement error present in our phenotypic data, for
example, smoking data was collected via self-report, and
there may be biases present in this data because of this.
In addition, measurement error may be present in the
genotyping data and methylation data. Finally, the DNA
methylation data was collected from blood samples
which may not be indicative of other tissue methylation
levels such as adipose tissue which may be more relevant
in a study looking at potential causal relationships
between BMI and DNAm. The overall agreement
between blood and adipose DNA methylation is fairly
low. For example, Huang et al. found that only 5.2% of
CpG sites have correlation above 0.5 between sample-
matched blood and adipose DNA methylation profiles
[33]. However, there are some important similarities
between the tissues with respect to BMI. Huang et al.
reported that the similarity of adipose to blood DNA
methylation is higher in individuals with higher BMI.
Dick et al. observed similar associations of HIF3a CpG
site cg2289107 in the blood and adipose tissue [10].
Conclusions
In conclusion, our study finds that DNA methylation
scores, as have so far been generated, are unlikely to be
predictive of future BMI using earlier DNA methylation
levels and therefore is more appropriately considered a
biomarker. This indicates that conducting EWAS using
DNAm values and trait values measured at the same
time point is not an effective strategy when attempting
to create predictors. Therefore, future studies should
perform EWAS that test for early DNAm values against
later health outcomes to evaluate whether this may
enable creating an effective predictor, which could then
be tested in other populations.
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